Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05966649

Synbiotics in Patients at RIsk fOr Preterm Birth

Prematurity remains the main cause of death and serious health problems in new-borns. Besides the need for hospitalization and medical interventions in the first weeks or months of the new-borns' life, prematurity can cause long-lasting health problems (e.g. multiple hospital admissions, developmental delay, learning difficulties, motor delay, hearing or eye problems, ...). Moreover, prematurity places an enormous economic burden on the society. Aside from the medical problems and the financial cost, the emotional stress and psychological impact on the parents, siblings and other family members should not be underestimated.

Previous preterm delivery (before 37 weeks of pregnancy) increases the risk for recurrent preterm delivery in a subsequent pregnancy. Therefore, these women should be considered as 'high risk' for preterm birth.

Infections ascending from the vagina may be an important cause of preterm delivery in certain cases. Some women have an abnormal vaginal microbiome and are therefore at risk for infections and preterm birth. On the other hand, the vaginal flora is more stable and resistant to infections in healthy pregnant women who deliver at term (after 37 weeks of gestation).

Synbiotics are a mixture containing probiotics and prebiotics. Probiotics are living bacteria with potential beneficial effects that can be used safely in pregnancy, while prebiotics are consumed by the bacteria. It is known that probiotics, when used for a long period of time, can maintain a healthy and stable vaginal flora that may protect against infections. In this study, pregnant patients with a history of preterm birth will be included in the first trimester of pregnancy to start with synbiotics or placebo. The investigators will examine the effect of synbiotics on the vaginal flora and on the pregnancy duration. The hypothesis is that synbiotics, when started early in the pregnancy, can change the disturbed vaginal flora into a stable micro-environment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Universitaire Ziekenhuis Antwerpen, Edegem, Antwerpen, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed written informed consent must be obtained before any study assessment is performed;
  • 18 years of age or older;
  • Singleton pregnancy;
  • Pregnancy consultation between 8 and 10 weeks gestation.
  • At least one of the following risk factors for spontaneous preterm birth:
  • Prior spontaneous preterm birth, defined as delivery between 24 and 36 weeks following PPROM, preterm labor or cervical insufficiency
  • PPROM ≤36 weeks in previous pregnancy
  • Prior spontaneous second-trimester pregnancy loss, defined as PPROM, preterm labor or cervical insufficiency with birth between 14 and 24 weeks.

Exclusion criteria

  • Patients who are already using pro-, pre- or synbiotics and not willing to stop
  • Multiple pregnancy
  • Need for primary (type 1) cerclage
  • Inflammatory bowel disease
  • Known congenital uterine anomaly
  • History of LLETZ conization

Treatment and study plan

Synbiotics

Other

Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.

Placebo

Other

Matching placebo

Primary outcomes

  1. Gestational age at delivery

    Time frame: Through study completion - at delivery

Secondary outcomes

  1. Incidence of PTB, defined as GA at delivery < 37 weeks

    Time frame: Through study completion - at delivery

  2. Proportion of PTB in different categories

    Time frame: Through study completion - at delivery

    • of patients that deliver < 28 weeks: extreme PTB
    • of patients that deliver from 28 until 37 weeks: very PTB
    • of patients that deliver from 32 until 37 weeks: moderate to late PTB
  3. PPROM

    Time frame: Up to 34 weeks from the date of randomization

    Incidence

  4. PPROM

    Time frame: Up to 34 weeks from the date of randomization

    Gestational age at PPROM

  5. PPROM

    Time frame: Up to 34 weeks from the date of randomization

    Time to delivery

  6. Composition of the vaginal microbiome

    Time frame: Assessed 3 times during the study period: at randomization, 11-13 weeks after randomization (at gestational age 19-21 weeks), and 21-23 weeks after randomization (29-31 weeks of gestation)

    The vaginal microbiome will be assessed throughout pregnancy at 4 well-defined stages of pregnancy (9, 20, 30 weeks and at delivery) and at admission at the MIC unit for preterm labor, PPROM or cervical insufficiency.

  7. Incidence of neonatal admissions

    Time frame: Neonatal admission at a neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)

  8. Duration of neonatal admissions

    Time frame: Neonatal admission at a neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)

  9. Incidence of maternal admissions

    Time frame: Up to 34 weeks from the date of randomization

  10. Duration of maternal admissions

    Time frame: Up to 34 weeks from the date of randomization

  11. Quality Of Life during pregnancy and during neonatal admission at a neonatal intensive care unit

    Time frame: Trough study completion, on average 1 year

    Using EQ5D questionnaire (5 questions and scale from 1 to 100)

  12. Neonatal outcome: infectious parameters

    Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)

    Sepsis (early, late and culture negative), number of episodes (min 72 hours) of antibiotic treatment, duration of antibiotic treatment in days

  13. Neonatal outcome: bronchopulmonary dysplasia (BPD)

    Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)

    Proportion of each category (no, mild, moderate and severe)

  14. Neonatal outcome: intraventricular haemorrhage

    Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)

    Incidence

  15. Neonatal outcome: periventricular leukomalacia

    Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)

    Incidence

  16. Neonatal outcome: respiratory support

    Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)

    Need for respiratory support (CPAP: continuous positive airways pressure, non-invasive positive pressure ventilation or mechanical endotracheal ventilation) and the duration of respiratory support in days. Use and administration of surfactant

  17. Neonatal outcome: retinopathy

    Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)

    Incidence

  18. Neonatal outcome: neonatal morbidity

    Time frame: During the admission at the neonatal intensive care unit (when the neonate is admitted at a neonatal intensive care unit within 7 days of delivery)

    Incidence

  19. Neonatal outcome: birth weight

    Time frame: After the neonate is born

Other outcomes

  1. Effect of antibiotics on the vaginal microbiome

    Time frame: During pregnancy until 28 days after PPROM

    When the patient is admitted in case the pregnancy was complicated with PPROM

  2. Effect on the gastrointestinal microbiome of the neonate in case of PPROM

    Time frame: Between 13 to 36 weeks from the date of randomization

    When the neonate is born after a pregnancy complicated with PPROM

  3. Placental microbiome in case of preterm birth

    Time frame: Between 13 to 36 weeks from the date of randomization

    In case the pregnancy was complicated with preterm birth (delivery before 37 weeks of gestation)

Study contacts

Contact information is provided by the study sponsor or research team.

Caroline Van Holsbeke, PhD

CONTACT

[email protected]

003289804057

Katrien Nulens, MD

CONTACT

[email protected]

003289804125

Sponsors and collaborators

Lead sponsor

Ziekenhuis Oost-Limburg

Other

Collaborators

  • Federaal Kenniscentrum voor Gezondheidszorg, Belgium

Registry information

Official study title

Synbiotics in Patients at RIsk fOr Preterm Birth: a Multi-center Double-blind Randomized Placebo-controlled trIal

Acronym: PRIORI

Important dates

Study start
2023
Primary completion
2028
Study completion
2029
First posted
Jul 28, 2023
Registry last updated
Feb 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.